CaltechAUTHORS
Published February 10, 2025 | Published
Journal Article Open

Klebsiella pneumoniae Glycoconjugate Vaccine Leads Based on Semi-Synthetic O1 and O2ac Antigens

Sianturi, Julinton1 ORCID icon
Weber, Fabienne1, 2
Singh, Rajat Kumar1, 2, 3
Lingscheid, Tilman4 ORCID icon
Tober‐Lau, Pinkus4 ORCID icon
Kurth, Florian4, 5 ORCID icon
Fries, Bettina C.6, 7
Seeberger, Peter H.1, 2 ORCID icon
  • 1. ROR icon Max Planck Institute of Colloids and Interfaces
  • 2. ROR icon Freie Universität Berlin
  • 3. ROR icon California Institute of Technology
  • 4. ROR icon Charité - University Medicine Berlin
  • 5. ROR icon German Center for Lung Research
  • 6. ROR icon Stony Brook University
  • 7. ROR icon Northport VA Medical Center
An error occurred while generating the citation.

Abstract

Klebsiella pneumoniae (KP) is a common opportunistic pathogen that emerged as a new critical threat to human health, due to its hypervirulence and widespread resistance against many antibiotics, including carbapenems. Alternative intervention strategies such as vaccines are not available. Cell-surface lipopolysaccharides (LPS) and capsular polysaccharides (CPS) are attractive targets for vaccine development. We present a method to synthesize LPS substructures, covering over 70 % of virulent KP strains that were used to characterize the antibody repertoire of infected patients. Thereby, glycoconjugate vaccine leads against the Klebsiella pneumoniae serotypes O1, O2a, O2afg and O2ac have been identified.

Copyright and License

© 2024 The Author(s). Angewandte Chemie International Edition published by Wiley-VCH GmbH. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

Acknowledgement

We thank the Max-Planck Society for generous financial support and open access funding by project DEAL. We thank the members of the Pa-COVID-19 Study Group (see Supporting Information) for providing and collecting sera samples. B.C.F. is supported by Veterans Administration (VA) Merit I01B 003741–01A2 (B.C.F.). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH, VA, or the United States government. We hereby acknowledge Eva Settels for support in HPLC- purification. We thank Dr. C. Roth, Dr. K. Pradhan, Ms. P. Priegue and Dr. M. G. Ricardo for reviewing the manuscript. Open Access funding enabled and organized by Projekt DEAL.

Data Availability

The data that support the findings of this study are available in the supplementary material of this article.

Supplemental Material

Supporting Information: anie202419516-sup-0001-misc_information.pdf

Files

Angew Chem Int Ed - 2024 - Sianturi - Klebsiella pneumoniae Glycoconjugate Vaccine Leads Based on Semi‐Synthetic O1 and.pdf

Additional details

Funding Dates Caltech Custom Metadata
Created:
March 14, 2025
Modified:
March 14, 2025